Denali Therapeutics Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Denali Therapeutics Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $0 | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $0 | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $330.53M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $108.46M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $48.66M | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $335.66M | Feb 27, 2023 |
| FY2021 | Dec 31, 2019 | $26.68M | Feb 28, 2022 |
| FY2020 | Dec 31, 2018 | $129.16M | Feb 26, 2021 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $0 | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $0 | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $330.53M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $105.07M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $48.66M | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $335.56M | Feb 27, 2023 |
| FY2019 | Dec 31, 2019 | $4.67M | Feb 27, 2020 |
| FY2019 | Sep 30, 2019 | $13.60M | Feb 27, 2020 |
| FY2019 | Jun 30, 2019 | $4.20M | Feb 27, 2020 |
| FY2019 | Mar 31, 2019 | $4.21M | Feb 27, 2020 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($512.54M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | ($422.77M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | ($145.22M) | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | ($325.99M) | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | ($290.58M) | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $71.14M | Feb 27, 2023 |
| FY2019 | Dec 31, 2019 | ($54.03M) | Feb 27, 2020 |
| FY2019 | Sep 30, 2019 | ($46.26M) | Feb 27, 2020 |
| FY2019 | Jun 30, 2019 | ($58.34M) | Feb 27, 2020 |
| FY2019 | Mar 31, 2019 | ($38.99M) | Feb 27, 2020 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($555.34M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | ($487.34M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | ($196.70M) | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | ($340.74M) | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | ($295.75M) | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $62.72M | Feb 27, 2023 |
| FY2019 | Dec 31, 2019 | ($57.76M) | Feb 27, 2020 |
| FY2019 | Sep 30, 2019 | ($50.16M) | Feb 27, 2020 |
| FY2019 | Jun 30, 2019 | ($62.76M) | Feb 27, 2020 |
| FY2019 | Mar 31, 2019 | ($42.51M) | Feb 27, 2020 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $418.78M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $396.44M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $423.88M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $358.73M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $265.35M | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $212.62M | Feb 27, 2023 |
| FY2021 | Dec 31, 2019 | $193.38M | Feb 28, 2022 |
| FY2020 | Dec 31, 2018 | $143.18M | Feb 26, 2021 |
| FY2019 | Dec 31, 2017 | $74.46M | Feb 27, 2020 |
| FY2018 | Dec 31, 2016 | $75.70M | Mar 12, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($412.60M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | ($347.69M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | ($357.99M) | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | ($244.72M) | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | ($211.39M) | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $416.15M | Feb 27, 2023 |
| FY2021 | Dec 31, 2019 | ($151.58M) | Feb 28, 2022 |
| FY2020 | Dec 31, 2018 | $50.12M | Feb 26, 2021 |
| FY2019 | Dec 31, 2017 | ($76.64M) | Feb 27, 2020 |
| FY2018 | Dec 31, 2016 | ($71.91M) | Mar 12, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $9.50M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $15.91M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $12.94M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $17.83M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $8.50M | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $3.10M | Feb 27, 2023 |
| FY2021 | Dec 31, 2019 | $17.92M | Feb 28, 2022 |
| FY2020 | Dec 31, 2018 | $3.39M | Feb 26, 2021 |
| FY2019 | Dec 31, 2017 | $2.88M | Feb 27, 2020 |
| FY2018 | Dec 31, 2016 | $6.13M | Mar 12, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.14B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $1.37B | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $1.15B | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $1.46B | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | $1.40B | Feb 27, 2023 |
| FY2021 | Dec 31, 2020 | $1.60B | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | $553.23M | Feb 26, 2021 |
| FY2019 | Dec 31, 2018 | $661.98M | Feb 27, 2020 |
| FY2018 | Dec 31, 2017 | $486.72M | Mar 12, 2019 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $131.09M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $144.50M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $122.96M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $417.81M | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | $441.87M | Feb 27, 2023 |
| FY2021 | Dec 31, 2020 | $453.75M | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | $158.34M | Feb 26, 2021 |
| FY2019 | Dec 31, 2018 | $115.14M | Feb 27, 2020 |
| FY2018 | Dec 31, 2017 | $20.93M | Mar 12, 2019 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.01B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $1.23B | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $1.03B | Feb 26, 2026 |
| FY2025 | Dec 31, 2022 | $1.04B | Feb 26, 2026 |
| FY2024 | Dec 31, 2021 | $962.29M | Feb 27, 2025 |
| FY2023 | Dec 31, 2020 | $1.15B | Feb 28, 2024 |
| FY2022 | Dec 31, 2019 | $394.89M | Feb 27, 2023 |
| FY2021 | Dec 31, 2018 | $546.85M | Feb 28, 2022 |
| FY2020 | Dec 31, 2017 | $465.80M | Feb 26, 2021 |
| FY2019 | Dec 31, 2016 | ($94.15M) | Feb 27, 2020 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($2.05B) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | ($1.54B) | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | ($1.12B) | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | ($970.99M) | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | ($645.00M) | Feb 27, 2023 |
| FY2021 | Dec 31, 2020 | ($354.42M) | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | ($425.55M) | Feb 26, 2021 |
| FY2019 | Dec 31, 2018 | ($227.94M) | Feb 27, 2020 |
| FY2018 | Dec 31, 2017 | ($191.70M) | Mar 12, 2019 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $205.33M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $174.96M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $127.11M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $218.04M | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | $293.48M | Feb 27, 2023 |
| FY2021 | Dec 31, 2020 | $507.14M | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | $79.45M | Feb 26, 2021 |
| FY2019 | Dec 31, 2018 | $77.12M | Feb 27, 2020 |
| FY2019 | Dec 31, 2017 | $218.38M | Feb 27, 2020 |
| FY2018 | Dec 31, 2016 | $39.85M | Mar 12, 2019 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (2) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | (2) | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | (1) | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | (2) | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | (2) | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | 0 | Feb 27, 2023 |
| FY2021 | Dec 31, 2019 | (2) | Feb 28, 2022 |
| FY2019 | Dec 31, 2018 | 0 | Feb 27, 2020 |
| FY2019 | Sep 30, 2018 | 0 | Feb 27, 2020 |
| FY2019 | Jun 30, 2018 | 0 | Feb 27, 2020 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (2) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | (2) | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | (1) | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | (2) | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | (2) | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | 0 | Feb 27, 2023 |
| FY2021 | Dec 31, 2019 | (2) | Feb 28, 2022 |
| FY2019 | Dec 31, 2018 | 0 | Feb 27, 2020 |
| FY2019 | Sep 30, 2018 | 0 | Feb 27, 2020 |
| FY2019 | Jun 30, 2018 | 0 | Feb 27, 2020 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 156.18M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | 144.22M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | 138.39M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | 135.97M | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | 122.28M | Feb 27, 2023 |
| FY2021 | Dec 31, 2020 | 120.53M | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | 96.19M | Feb 26, 2021 |
| FY2019 | Dec 31, 2018 | 94.66M | Feb 27, 2020 |
| FY2018 | Dec 31, 2017 | 87.48M | Mar 12, 2019 |